Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial

• Status: Completed
• Trial end date: 2021-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To observe and compare the clinical efficacy of cyclosporine 0.05% eye drops with Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3% in the treatment of Vernal Keratoconjunctivitis in developing regions of China.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Affiliated Hospital of Nanchang University
• Treatments: Cyclosporine; Cyclosporins; Loteprednol Etabonate; Ophthalmic Solutions; Tobramycin

Criteria

Inclusion criteria

• patients had a noticeable seasonal, and recurrent Itching, Discomfort(burning, stinging, and foreign body sensation), Photophobia and tears, Viscous discharge;

• Slit-lamp microscopy showed Conjunctival Hyperemia, Tarsal papillary, Limbal hypertrophy, Horner-Trantas dots, Keratitis in some patients;

• No other medication history in recent 2 weeks;

• Patients have high compliance and are willing to take drugs on time and return to the clinic in time

Exclusion criteria:

• with other related immune diseases or other drug use history in recent 2 weeks;

• Patients with evident and severe organic diseases or mental diseases;

• Low compliance, unable to take drugs on time or fail to return to the clinic on time.